Twice-yearly exams unnecessary for patients taking quetiapine
References (5)
Physicians' Desk Reference
(2004)- et al.
Cataracts and quetiapine
Am J Psychiatry
(2001)
Cited by (20)
Drugs Affecting the Central Nervous System
2020, Drug-Induced Ocular Side Effects, Eigtht EditionAssociation between antipsychotic drug use and cataracts in patients with bipolar disorder: A population-based, nested case-control study
2017, Journal of Affective DisordersCitation Excerpt :Furthermore, our results showed that among patients with BD, past and continuous users of AAPs had reduced odds of cataract development, which is similar to the study results conducted by Pakzad-Vaezi et al. (2013) demonstrating a protective association between the use of AAPs and risk of clinically significant cataracts requiring surgery. On the other hand, most previous studies demonstrated that use of AAPs is not associated with an increased risk of cataract development in patients with schizophrenia (Chou et al., 2016; Fraunfelder, 2004; Souza et al., 2008; Ucok and Gaebel, 2008). However, due to different study population recruited in these studies, it is difficult to make direct comparisons between our study results with those in previous studies.
Prevalence of diagnosed ocular disease in veterans with serious mental illness
2016, General Hospital PsychiatryCitation Excerpt :In a case–control study, McCarty et al. [3] found that the prevalence of anterior subcapsular cataract in patients with schizophrenia was 26%. While quetiapine has been implicated in cataract formation, this association is controversial [21–23]. While the prevalence of type 2 diabetes in individuals with SMI is two to three times higher than in the general population [16], we found SMI to be protective of ophthalmic complications of diabetes in our sample.
Use of atypical antipsychotics and risks of cataract development in patients with schizophrenia: A population-based, nested case-control study
2016, Schizophrenia ResearchCitation Excerpt :Among individual AAPs, there has been concern about a causal link between quetiapine and lens opacities in humans because focal triangular cataracts were found in beagle dogs receiving quetiapine at four times the maximum human dose for six or 12 months (Shahzad et al., 2002). In the present study, we did not identify an increased risk of cataract development in SZ patients continuously treated with quetiapine, consistent with previous reports (Fraunfelder, 2004; Laties et al., 2000, 2015; Lieberman et al., 2005; Nasrallah et al., 1999; Whitehorn et al., 2004). Furthermore, similar to previous reports (Shahzad et al., 2002), we did not identify an increased risk of cataract development in continuous users of olanzapine, risperidone, or ziprasidone.
Part 7 - Drug-induced ocular side effects
2014, Drug-Induced Ocular Side Effects: Clinical Ocular ToxicologyCase of rapid bilateral cataract development in teenager using selective serotonin reuptake inhibitors
2014, Canadian Journal of Ophthalmology
This study was supported in part by an unrestricted grant from Research to Prevent Blindness, New York, New York and by the National Registry of Drug-Induced Ocular Side Effects, Casey Eye Institute, Oregon Health & Science University, Portland, Oregon.
The authors are indebted to the national centers in this study that contributed data. Their opinions and conclusions, however, are not necessarily those of the various centers or of the WHO. The author has no proprietary interest in the materials presented herein.